Coloplast CEO on expectations: "There are many swing factors"

When Coloplast's CFO Anders Lonning-Skovgaard looks from one Covid-stricken year to the next, he assumes that health authorities worldwide have improved their ability to handle the coronavirus pandemic and that Coloplast and its growth target will be less affected than previously, if infections and hospitalizations go back on the rise.

EVP Coloplast EVP and CFO Anders Lonning-Skovgaard. | Photo: Coloplast / PR

After a year of troubled waters because of the Covid-19 pandemic, Coloplast has a feeling it's headed towards a more positive and stable time. The Danish medtech firm has positive expectations for the coming fiscal year, where it aims to have organic growth at 7-8 percent and earnings at between 31-32 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs